Conference Reports for NATAP

Back

AASLD The Liver Meeting November Fri, Nov 12 - Mon, Nov 15, 2021   This information is brought to you by NATAP and is not sponsored by, nor a part of, the American Association for the Study of Liver Diseases or The Liver Meeting® or The Liver Meeting Digital Experience ™     LOW HBsAg LEVELS MAINTAINED FOLLOWING CESSATION OF THE GALNAC-siRNA, AB-729, IN CHRONIC HEPATITIS B SUBJECTS ON NUCLEOS(T)IDE ANALOGUE THERAPY (01/15/22)   Safety, PK, PD and antiviral activity of TLR7 agonist RO7020531 in patients with chronic hepatitis B not receiving antiviral treatment: a phase 1 study (12/28/21)   LIVER-DIRECTED TARGETING OF PD-L1 WITH RO7191863, A LOCKED NUCLEIC ACID, IN CHRONIC HEPATITIS B: FIRST REPORT OF PHASE 1 TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS (12/28/21)   Efficacy and Safety of the siRNA JNJ-3989 and/or the Capsid Assembly Modulator JNJ-6379 for the Treatment of Chronic Hepatitis B Virus Infection : Results From the Phase 2b REEF-1 Study (12/15/21)   EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor Demonstrates Significant HBV DNA and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic Hepatitis B Infected Patients (12/14/21)   EDP-514, A NOVEL PANGENOTYPIC CLASS II HEPATITIS B VIRUS CORE INHIBITOR: PRELIMINARY RESULTS OF A 28-DAY PHASE 1b STUDY IN NUC-SUPPRESSED CHB PATIENTS (12/14/21)   Safety and pharmacokinetics of ABI-H3733, a novel second-generation HBV core inhibitor: Results from a Phase 1a study in healthy volunteers (12/14/21)   Preclinical characterization of ABI-4334, a novel, highly potent core inhibitor for the treatment of chronic hepatitis B virus infection (12/14/21)   HBV pgRNA and DNA both rebound immediately following discontinuation of the core inhibitor vebicorvir despite continued NrtI treatment in patients with HBeAg positive chronic hepatitis B virus infection: findings from a phase 2 open-label study (12/14/21)   LONG-TERM EVALUATION OF HCV RE-INFECTION RATES AMONG INNER CITY VULNERABLE POPULATIONS (12/14/21)   ALG-005398 is a Potent Non-HAP Class I HBV Capsid Assembly Modulator that Strongly Reduces HBsAg Levels In Vivo (12/13/21)   ALG-020572, a GalNAc-conjugated Antisense Oligonucleotide, Demonstrates In Vivo Efficacy and Favorable Preclinical Profile for the Treatment of Chronic Hepatitis B (12/13/21)   TRIPLE COMBINATION OF ANTI-HEPATITIS B VIRUS DRUGS DEMONSTRATES SYNERGISTIC ACTIVITY IN VITRO (12/13/21)   THE PHARMACOKINETIC AND SAFETY PROFILES OF RO7445482 siRNA [RG6346] ARE SIMILAR BETWEEN ASIAN AND NON-ASIAN HEALTHY VOLUNTEERS AND CHRONIC HEPATITIS B PATIENTS IN A PHASE 1 STUDY (12/13/21)   Tenofovir Alafenamide for Pregnant Chinese Women with Active Chronic Hepatitis B: A Multicenter Prospective Study (12/13/21)   Point-of-Care 60-minute Rapid HCV RNA Screening for IDUs Studies at AASLD & FDA Approval (12/10/21)   Hepatitis D Delta Overview; New AASLD 2021 Treatment Studies (12/06/21)   HBV Nuc Withdrawal -Cautionary Study Results at AASLD 2021 (12/06/21)   Hepatitis D (Delta) at AASLD 2021 (12/06/21)   CONCURRENT FATTY LIVER IS ASSOCIATED WITH HIGHER RISK OF HEPATOCELLULAR CARCINOMA AND MORTALITY IN PATIENTS WITH CHRONIC VIRAL HEPATITIS (12/03/21)   HCV Prior Authorization & Elimination Barriers - One Small Step for Rhode Island Medicaid, One Giant Leap Towards Hepatitis C Elimination (12/03/21)   RESULTS OF A TEN YEAR PROSPECTIVE OBSERVATIONAL STUDY ON ACUTE HEPATITIS C IN HCV-MONO- AND HCV/HIV- COINFECTED PATIENTS (12/03/21)   TREATMENT OF HEPATITIS C RECURRENCE POST LIVER TRANSPLANT WITH ORAL DIRECT ACTING ANTI-VIRAL: A REAL-WORLD EXPERIENCE FROM A SATELLITE CLINIC IN THE SOUTHERN UNITED STATES (12/03/21)   IDENTIFYING PERSISTING LIVER DISEASE AND LIVER ASSOCIATED MORBIDITY AND MORTALITY AFTER VIRAL CURE OF HCV - DATA FROM THE GERMAN HEPATITIS C-REGISTRY (DHC-R) (12/02/21)   SIMULTANEOUS HEPATITIS B AND C SCREENING IN AN EMERGENCY DEPARTMENT: A BROAD LINKAGE TO CARE STRATEGY (12/02/21)   RARE HCV GENOTYPES: PREVALENCE AND RESISTANCE-ASSOCIATED SUBSTITUTIONS IN DAA-NAÏVE AND DAA-EXPERIENCED PATIENTS (12/01/21)   HIGH RATE OF HEPATITIS C REINFECTION IN AN ADULT CUSTODIAL SETTING IN AUSTRALIA (12/01/21)   LONG-TERM PERSISTENCE OF RESISTANCE-ASSOCIATED SUBSTITUTIONS (RASS) AFTER DAA TREATMENT FAILURE IN PATIENTS WITH CHRONIC HCV INFECTION (12/01/21)   HEPATITIS C VIRUS REINFECTION AFTER SUCCESSFUL TREATMENT WITH DIRECT ACTING ANTIVIRAL THERAPY IN CANADA (12/01/21)   IMPLEMENTATION OF RAPID POINT-OF-CARE DIAGNOSTIC SYSTEMS TO SUPPORT HCV MICRO-ELIMINATION STRATEGIES IN A TERTIARY HOSPITAL IN SPAIN (12/01/21)   IMPLEMENTATION OF ROUTINE OPT OUT HEPATITIS C TESTING IN THE PHILADELPHIA JAIL SYSTEM (12/01/21)   POINT-OF-CARE TESTING FOR HEPATITIS C IN PUBLIC CLINICAL LABORATORIES REVEALS SIGNIFICANT RATES OF HIDDEN HCV AMONG ELDERLY POPULATION IN SOUTHERN ITALY (12/01/21)   THE IMPACT OF IMMIGRATION ON THE NATIONAL HEPATITIS B PREVALENCE IN THE UNITED STATES (11/30/21)   Liver Stiffness-Based Agile Scores Predict Disease Progression in Patients With Advanced Fibrosis Due to NASH (11/30/21)   Combination Treatments Including CILO and/or FIR in Addition to SEMA Lead to Greater Improvements and Normalization of Cell Death Marker CK18 M30 in Patients With NASH (11/30/21)   Impact of Modest Weight Reduction on Serum Markers, Liver Histology, and Disease Progression in Patients with Advanced Fibrosis due to NASH (11/30/21)   FXR Agonism Elevates Circulating Levels of the Pruritogenic Cytokine IL-31 (11/30/21)   Pharmacokinetics of Firsocostat, an Acetyl-CoA Carboxylase (ACC) Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist, in Participants with Severe Renal Impairment (11/30/21)   Combination of an Acetyl-CoA Carboxylase Inhibitor and Fibroblast Growth Factor-19 Reduced Tissue Triglyceride Content and Fibrosis in a 3D Human Liver Microtissue Model of Nonalcoholic Steatohepatitis (11/30/21)   MILD NAFLD IS COMMON IN SEVERELY OBESE ADOLESCENTS AND IMPROVES SIGNIFICANTLY FOLLOWING BARIATRIC SURGERY (11/30/21)   Impact of Modest Weight Reduction on Serum Markers, Liver Histology, and Disease Progression in Patients with Advanced Fibrosis due to NASH (11/30/21)   Pentavalent HCV Vaccine Candidate Elicits Broadly Neutralizing Antibodies to Neutralization-Resistant Variants (11/30/21)   PROTEASE INHIBITORS (PI) IN TREATMENT OF HEPATITIS C AND THE RISK OF HEPATIC DECOMPENSATION: A SYSTEMATIC REVIEW OF ALL PI USE VS SOFOSBUVIR + NS5A INHIBITOR +/-RIBAVIRIN (11/30/21)   POTENTIAL COST-EFFECTIVENESS OF A MACHINE LEARNING ALGORITHM TO IDENTIFY UNDIAGNOSED HEPATITIS C PATIENTS IN THE UNITED STATES (11/30/21)   PROVISION OF HEPATITIS C CARE IN A FEDERALLY QUALIFIED HEALTH CENTER DURING THE COVID-19 PANDEMIC AND BEYOND - telemedicine & delivery of DAA medications (11/30/21)   ASSOCIATION BETWEEN DAILY ASPIRIN THERAPY AND HEPATOCELLULAR CARCINOMA ACCORDING TO METABOLIC RISK FACTOR BURDEN IN PATIENTS WITH CHRONIC HEPATITIS B (11/30/21)   MODIFIED ECHO MODEL TO INCREASE ACCESS TO HEPATITIS C TREATMENT: A HYBRID OF ECHO AND CO-MANAGEMENT BETWEEN SPECIALTY PROVIDERS AND COMMUNITY PROVIDERS & Rapid Same Day Models of Treatment (11/30/21)   Open access case consultations with HCV experts in [rural] Michigan for Opioid Users AN OPEN ACCESS HEPATITIS C VIRUS CASE CONSULTING PROGRAM TO EXPAND FRONTLINE COMMUNITY PROVIDER CAPACITY (11/30/21)   PARTNERSHIPS FOR ELIMINATION: AMBULATORY CARE CLINICAL PHARMACISTS DISMANTLING BARRIERS TO HEPATITIS C CURE at St Barnabas in NJ (11/30/21)   Treat HCV Early; SOF/DCV Had Lower SVR Rates (11/30/21)   HCV TREATMENT AMONG ACTIVE INNER CITY DRUG USERS WITH GLECAPREVIR/PIBRENTASVIR: THE GRAND PLAN STUDY (11/30/21)   Preliminary Results From a Phase 2 Study Evaluating VIR-2218 Alone and in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis B Infection (11/23/21)   ARO-HSD, an investigational RNAi therapeutic, demonstrates reduction in ALT and hepatic HSD17B13 mRNA and protein in patients with NASH or suspected NASH (11/23/21)   Rapid HBsAg Reduction in Chronic Hepatitis B Virus Infection: Preliminary Results From a Phase 1 Study Evaluating a Single Dose of VIR-3434, a Novel Neutralizing, Vaccinal Monoclonal Antibody (11/23/21)   Understanding Patient Experiences with Chronic Hepatitis B Virus and its Treatments (11/23/21)   Changes in Viral Antigens are More Strongly Associated with HBV pgRNA than HBV DNA in Studies of Vebicorvir and NrtI in Treatment-naïve Patients with Chronic HBV Infection (11/23/21)   EFFICACY OF LONG-TERM TREATMENT OF CHRONIC HEPATITIS D PATIENTS WITH BULEVIRTIDE - RESULTS OF A "REAL WORLD" STUDY (11/23/21)   TREATMENT WITH BEPIROVIRSEN (GSK3228836) LEADS TO HEPATITIS B SURFACE ANTIGEN (HBsAg) REDUCTION AND CYTOKINE/ CHEMOKINE RESPONSES LINKED TO INNATE AND ADAPTIVE IMMUNITY IN A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (11/23/21)   Amino Acid Substitutions in the Inhibitor Binding Pocket of HBV Core Protein Confer Differential Changes in Susceptibility to Three Generations of HBV Core Inhibitors (11/23/21)   Analysis of the longer-term safety profile of the hepatitis B virus core inhibitor ABI-H0731 in an open-label extension study (11/23/21)   Persistently detectable serum HBV DNA and pgRNA is associated with subsequent hepatocellular carcinoma development in chronic hepatitis B patients receiving chronic NRTI treatment (11/23/21)   GLOBAL TRENDS IN CAUSE-SPECIFIC MORTALITY AND DISABILITY ADJUSTED LIFE YEARS RELATED TO HEPATITIS B VIRUS AND HEPATITIS C VIRUS FROM 2010 TO 2019 (11/22/21)   BENEFITS OF DAA TREATMENT ON MORTALITY RELATED TO EXTRAHEPATIC MANIFESTATIONS AMONG PEOPLE WHO INJECT DRUGS: A POPULATION-BASED STUDY IN BRITISH COLUMBIA, CANADA (11/22/21)   Exploring the Patient Voice in Hepatitis B Care, Education, and Cure Research (11/22/21)   CHRONIC HEPATITIS C INFECTION AND INCIDENCE OF EXTRAHEPATIC CANCERS IN A CANADIAN POPULATION-BASED COHORT (11/22/21)   HCV CASCADE OF CARE [Big Gaps] AND NEXT STEPS FOR HCV ELIMINATION IN THE UNITED STATES FOLLOWING THE COVID-19 PANDEMIC - new updated improved HCV screening guidelines needed including for pregnant women & high-risk populations (11/22/21)   IMPACT OF HCV VIRAL PARAMETERS ON PREGNANCY COMPLICATIONS AND RISK OF MOTHER-TO-CHILD TRANSMISSION (11/22/21)   HCC Risk Factors After HCV Cure Differ With vs Without Cirrhosis and Over Time - Mark Mascolini (11/20/21)   Safety and Efficacy at 4 Years in Post-Liver Transplant Patients With Chronic Kidney Disease Receiving Tenofovir Alafenamide [vs TDF] for HBV Prophylaxis - (11/20/21)   Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate in Chronic HBV Patients Treated for 2 Years - (11/20/21)   HDV Hospital Admissions Rare-But Sometimes Severe-in United States - Mark Mascolini (11/20/21)   Safety and Preliminary Efficacy of the Farnesoid X Receptor Agonist Cilofexor in a 96-week Open-label Extension of a Phase 2 Study of PSC - (11/20/21)   LIVER-DISTRIBUTED FXR AGONIST TERN-101 DEMONSTRATES FAVORABLE SAFETY AND EFFICACY PROFILE IN NASH PHASE 2a LIFT STUDY - (11/20/21)   Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 demonstrates robust clinical efficacy and safety in a global Phase 2 randomized placebo-controlled NASH trial conducted in the US and China - (11/20/21)   FASN Inhibitor TVB-2640 Cuts Liver Fat 28% in US/China NASH Trial - Mark Mascolini (11/20/21)   DE NOVO HEPATOCELLULAR CARCINOMA OCCURRENCE FOLLOWING THE HCV VIRAL ERADICATION BY DIRECT ANTING ANTIVIRALS (DAA): MEDIUM TO LONG TERM OBSERVATIONS FROM THE ONGOING PITER COHORT - (11/19/21)   HTD1801 Lowers Liver Fat Content With Presumed NASH and Diabetes - Mark Mascolini (11/19/21)   MOLECULAR AND CLINICAL EPIDEMIOLOGY OF HEPATITIS D VIRUS INFECTION IN CANADA - (11/19/21)   Low adherence to guidelines recommendations for hepatitis D testing in HBsAg-positive patients leads to high undiagnosis rates - (11/19/21)   Hepatitis D-Associated Hospitalizations in the United States: 2010-2018 - (11/19/21)   Over 90% of Clinicians Ignore EACS Hep D Screening Advice - Mark Mascolini (11/19/21)   Largest Case Series of SOF + GLE/PIB + RBV for Deep HCV Salvage: 100% SVR12 - (11/19/21)   Safety and Efficacy of 2 mg Bulevirtide in Patients with Chronic HBV/HDV Co-Infection: First Real-World Results - (11/17/21)   Prevalence and Characteristics of Hepatitis Delta in the United States: an Analysis of All-Payer Claims Databases - (11/17/21)   ETHNIC VARIATIONS IN CLINICAL PRESENTATION AND TREATMENT ELIGIBILITY FOR HEPATITIS DELTA VIRUS INFECTION AT A US REFERRAL CENTER - (11/17/21)   Worse Antibody and Cellular Response to SARS-CoV-2 Vax With Cirrhosis - Mark Mascolini (11/17/21)   The impact of the COVID-2019 pandemic on HCV testing and treatment in the United States - (11/17/21)   INTERFERON DRIVES HEPATITIS C VIRUS SCARRING OF THE EPIGENOME AND CREATES TARGETABLE VULNERABILITIES FOLLOWING VIRAL CLEARANCE - (11/17/21)   NATIONAL AND LOCAL POLICY CHANGES ARE ASSOCIATED WITH INCREASED HEPATITIS C VIRUS TREATMENT RATES, BUT DISPARITIES REMAIN - (11/17/21)   LONG-TERM ASSESSMENT OF RECURRENCE OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS C AFTER VIRAL CURE BY DAAs - (11/17/21)   HEPATITIS C TREATMENT IN THE UNITED STATES, 2014-2020 numbers of treated is "below that needed to ensure elimination in USA by 2030, increased screening needed, remove all rstrictions" - (11/17/21)   PROTEASE INHIBITORS (PI) IN TREATMENT OF HEPATITIS C AND THE RISK OF HEPATIC DECOMPENSATION: A META-ANALYSIS OF PI REGIMEN SAFETY - (11/17/21)   HEALTH DISPARITIES IN LIVER TRANSPLANT EVALUATION BY THE PATIENT'S NEIGHBORHOOD DEPRIVATION - "The most deprived group had a significantly higher proportion of patients that were black" - (11/17/21)   Global Status Update on the HCV Prevalence and Cascade of Care Entering 2020 - (11/17/21)   TAF and TDF Safe, Effective for Pregnant Mothers With HBV and Infants - Mark Mascolini (11/16/21)   Strong intrahepatic decline of hepatitis D virus RNA and antigen after 48 weeks of treatment with Bulevirtide in chronic HBV/HDV co-infected patients: Interim results from a multicenter, open-label, randomized phase 3 clinical trial (MYR301) - (11/16/21)   A COMMUNITY-BASED TRIAL OF HEPATITIS C TREATMENT AT POINT OF DIAGNOSIS FOR MARGINALIZED POPULATIONS: PRELIMINARY RESULTS FROM THE NO ONE WAITS (NOW) STUDY - (11/16/21)   Global HBV Cascade of Care - (11/16/21)   Nucleos(t)ide analogue withdrawal in chronic hepatitis B patients leads to limited sustained remission in the absence of HBsAg loss: results from the RETRACT-B study Sustained HBV Remission in Only 20% 4 Years After Nucs Stop Without HBsAg Loss - Mark Mascolini (11/16/21)   US Medicare Patients With NAFLD Get Less HCC Surveillance and Curative Therapy - Mark Mascolini (11/16/21)   INSTIs and DAAs Boost Liver Transplant Survival in HIV+ and HIV+/HCV+ in US - (11/16/21)   Rapid HCV Testing and Treating Young Drug Injectors Yields Higher SVR12 - Mark Mascolini (11/16/21)   Failure to Attain SVR With DAAs Tied to Shorter HCC-Free Survival - Mark Mascolini (11/16/21)   Excellent Efficacy and Safety of Sofosbuvir, Glecaprevir, Pibrentasvir and Ribavirin for Retreatment of Chronic Hepatitis C after Sofosbuvir, Velpatasvir and Voxilaprevir Failure - (11/16/21)   Exercise for 20 Weeks Tied to Lower Clotting Risk in Randomized NASH Trial - Mark Mascolini (11/15/21)   More Steatohepatitis Resolution With Low-Cal Mediterranean Diet Than With Low-Fat Diet - Mark Mascolini (11/15/21)   Incidence and clinical characteristics of hepatocellular carcinoma associated with nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis - Mark Mascolini (11/15/21)   Burden of Illness and Economic Impact of Nonalcoholic Steatohepatitis (NASH) in the United States According to the Presence of Obesity - (11/15/21)   Simple Tool Tells Primary Care Docs When to Refer People With NAFLD - Mark Mascolini - (11/15/21)   HIV is independently associated with elevated FibroScan-AST (FAST) score, a non-invasive measurement of non-alcoholic steatohepatitis with significant activity and fibrosis - Mark Mascolini - (11/15/21)   Global status update on the HCV prevalence and cascade of care entering 2020 - lack of progress - Mark Mascolini - (11/15/21)   HCV-RNA VIRAL LOAD FINGERSTICK ASSAY AS A SIMPLIFIED STRATEGY FOR SCREENING AND LINKAGE TO CARE OF PEOPLE WHO USE DRUGS ATTENDING ITALIAN ADDICTION TREATMENT CENTRES: A PILOT PROJECT - (11/15/21)   Rapid Hepatitis C Treatment Initiation in Young People Who Inject Drugs: Final Results from the HCV-Seek, Test & Rapid Treatment (HCV-ST&RT) Randomized Pilot Clinical Trial - (11/15/21)   HCC Incidence Threshold for Routine Surveillance is Much Lower in Hepatitis C Cirrhosis Individuals Who Achieve Virological Cure - (11/15/21)   Persistent COVID Symptoms, Weight Gain, Alcohol Use With Long COVID and Chronic Liver Disease - Mark Mascolini - (11/15/21)   Higher Baseline Comorbidities and Liver Disease Severity Among Patients With Hepatitis Delta Infection vs Hepatitis B Monoinfection: a National US Claims Database Analysis - (11/15/21)   Cost-Effectiveness Analysis of Treating All HBsAg+ Individuals in the United States - (11/15/21)   Preliminary Results From a Phase 2 Study Evaluating VIR-2218 Alone and in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis B Infection - (11/15/21)   HBV pgRNA and DNA both rebound immediately following discontinuation of the core inhibitor vebicorvir despite continued NrtI treatment in patients with HBeAg positive chronic hepatitis B virus infection: findings from a phase 2 open-label study - (11/15/21)   Severe Hepatitis Flare and Subsequent Mortality after Discontinuation of Oral Antiviral Treatment in Patients with Chronic Hepatitis B: a Population-based Study - (11/15/21)   Hospital Rate Falls More Than 12% With COVID Vax for Cirrhosis Patients - Mark Mascolini (11/15/21)   COVID Takes Big Bite Out of HBV/HCV Care in 37-Center Global Study - Mark Mascolini (11/15/21)   One in 5 With Cirrhosis Suffers Anxiety-1 in 12 Also Has Depression - Mark Mascolini (11/15/21)   HCC Incidence Threshold for Cost-Effective Surveillance Much Lower Than Prior Standard - Mark Mascolini (11/13/21)   Non-alcoholic Steatohepatitis is the Most Common Indication for Liver Transplantation among the Elderly: Data from the U.S. Scientific Registry of Transplant Recipients - (11/13/21)   Risk of Multiple Drug Interactions Potentially Linked to Safety in Patients Receiving Pangenotypic Direct-acting Antivirals for the Treatment of Hepatitis C - (11/13/21)   Nucleos(t)ide analogue withdrawal in chronic hepatitis B patients leads to limited sustained remission in the absence of HBsAg loss: Results from the RETRACT-B study Response after End of Treatment with Antivirals in Chronic Hepatitis B (RETRACT-B Study) - (11/13/21)   Severe Hepatitis Flare in Over 6% Stopping HBV Therapy in Taiwan - Mark Mascolini (11/13/21)   Safety and Efficacy of 2 mg Bulevirtide in Patients with Chronic HBV/HDV Co-Infection: First Real-World Results French Early Access Program - (11/13/21)   TREATMENT WITH BULEVIRTIDE IMPROVES PATIENT REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS DELTA (CHD): AN INTERIM EXPLORATORY ANALYSIS AT WEEK 24 - (11/13/21)   HBV and HCV are Each Associated with Adverse Pregnancy Complications: a 7-year Nationwide Inpatient Sample Study - (11/13/21)   USE OF SOFOSBUVIR/VELPATASVIR IN TEST AND TREAT STRATEGY IN FRANCE: SNAPSHOT ANALYSIS OF PROSPECTIVE COHORT STUDY HELIOS 3 - (11/12/21)   HDV seropositivity was common amongst HBsAg+ women enrolled in WIHS. 26 (22%) of the 117 HBsAg+ women were HDV seropositive - (11/12/21)   USE OF SOFOSBUVIR/VELPATASVIR IN TEST AND TREAT STRATEGY IN FRANCE: SNAPSHOT ANALYSIS OF PROSPECTIVE COHORT STUDY HELIOS 3 - (11/12/21)   A Case Series of Safety and Efficacy of Crushed Sofosbuvir/Velpatasvir in Hepatitis C Infected Patients - (11/12/21)   CIRRHOSIS IS ASSOCIATED WITH SIGNIFICANT ADVERSE PREGNANCY COMPLICATIONS: A 7-YEAR NATIONWIDE INPATIENT SAMPLE STUDY - (11/12/21)   SUCCESSFUL IMPLEMENTATION OF UNIVERSAL HCV SCREENING AT A SAFETY-NET HOSPITAL'S EMERGENCY DEPARTMENT DURING THE COVID-19 PANDEMIC - 6% Overall HCV prevalence: 13% in baby boomers; 4% in nonBBs, overall chronic infection 2.5%; low linkage to care - (11/12/21)   THE IMPACT OF THE COVID-19 PANDEMIC ON HCV TESTING AND TREATMENT IN THE UNITED STATES - Between February 2020 and March 2020, the predicted number of tests dropped significantly by 33% but started to improve; Treatment Initiation dropped by 31% - (11/12/21)   CIRRHOSIS IN HIV VERSUS NON-HIV PATIENTS - ANALYSIS OF DEMOGRAPHICS, OUTCOMES AND HEALTHCARE UTILIZATION FROM A NATIONAL DATABASE - Ethnic Disparities, PLWH Have Longer Hospital Stays & Greater Hospital Charges - (11/12/21)   HCC Risk Factors After SVR - LONGITUDINAL ASSOCIATIONS BETWEEN RISK FACTORS AND SUBSEQUENT RISK OF HEPATOCELLULAR CANCER IN PATIENTS WITH HEPATITIS C VIRUS INFECTION AND VIROLOGICAL CURE - (11/12/21)   Change in HCV Epidemiology From 2018 to 2019: A Comparison Between States With No Medicaid Restrictions and States With Several Medicaid Restrictions - (11/12/21)   Retreatment of Hepatitis C Virus-infected Patients Who Failed Glecaprevir/Pibrentasvir - (11/12/21)   Shorter Duration Hepatitis C Virus Treatment is Associated With Better Persistence to Prescription Fills in People Who Inject Drugs - (11/12/21)   Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study - (11/12/21)   Non-Overweight Patients with Nonalcoholic Fatty Liver Disease, Diabetes Fare Worse Than Overweight Patients Before and After Liver Transplant - (11/12/21)   The Need for Liver Transplants Is Skyrocketing Among Older Americans - (11/12/21)